Nelfinavir mesylate AG1343 en es it fr

Nelfinavir mesylate AG1343 Brand names, Nelfinavir mesylate AG1343 Analogs

Nelfinavir mesylate AG1343 Brand Names Mixture

  • No information avaliable

Nelfinavir mesylate AG1343 Chemical_Formula


Nelfinavir mesylate AG1343 RX_link

Nelfinavir mesylate AG1343 fda sheet

Nelfinavir_mesylate_AG1343 FDA

Nelfinavir mesylate AG1343 msds (material safety sheet)

Nelfinavir_mesylate_AG1343 MSDS

Nelfinavir mesylate AG1343 Synthesis Reference

No information avaliable

Nelfinavir mesylate AG1343 Molecular Weight

567.784 g/mol

Nelfinavir mesylate AG1343 Melting Point

349.84 oC

Nelfinavir mesylate AG1343 H2O Solubility

Slightly soluble

Nelfinavir mesylate AG1343 State


Nelfinavir mesylate AG1343 LogP


Nelfinavir mesylate AG1343 Dosage Forms

Tablet (oral - 250 mg, 625 mg); Powder (oral)

Nelfinavir mesylate AG1343 Indication

Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.

Nelfinavir mesylate AG1343 Pharmacology

Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Nelfinavir mesylate AG1343 Absorption

Well absorbed following oral administration.

Nelfinavir mesylate AG1343 side effects and Toxicity

Oral LD50 is over 5g/kg in rats. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.

Nelfinavir mesylate AG1343 Patient Information


Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic

Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.

Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.

The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.

VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.

Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.

Nelfinavir mesylate AG1343 Organisms Affected

Human immunodeficiency virus